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INCORPORATING LOW-DOSE EPIDEMIOLOGY DATA IN A CHLORPYRIFOS
RISK ASSESSMENT
Julie E. Goodman, Robyn L. Prueitt, and Lorenz R. Rhomberg  Gradient,
Cambridge, MA
 USEPA assessed whether epidemiology data suggest that fetal or early-life chlorpyrifos
exposure causes neurodevelopmental effects and, if so, whether they occur at exposures
below those causing the current most sensitive endpoint, 10% inhibition of blood acetyl-
cholinesterase (AChE). We previously conducted a hypothesis-based weight-of-evidence
analysis and found that a proposed causal association between chlorpyrifos exposure and
neurodevelopmental effects in the absence of AChE inhibition does not have a substantial
basis in existing animal or in vitro studies, and there is no plausible basis for invoking such
effects in humans at their far lower exposure levels. The epidemiology studies fail to show
consistent patterns; the few associations are likely attributable to alternative explanations.
Human data are inappropriate for a dose-response assessment because biomarkers were
only measured at one time point, may reflect exposure to other pesticides, and many val-
ues are at or below limits of quantification. When considered with pharmacokinetic data,
however, these biomarkers provide information on exposure levels relative to those in
experimental studies and indicate a margin of exposure of at least 1,000. Because animal
data take into account the most sensitive lifestages, the use of AChE inhibition as a regu-
latory endpoint is protective of adverse effects in sensitive populations.
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INTRODUCTION
Chlorpyrifos is an organophosphorus (OP) insecticide that was wide-
ly used for agricultural and residential pest control until 2001, when its
non-agricultural use was restricted in the United States (USEPA 2002).
Non-occupational human exposures occur mainly via ingestion of
residues in the diet, while dermal and inhalation pathways likely pre-
dominate for occupational exposure (Eaton et al. 2008).
Chlorpyrifos is highly absorbed after oral and inhalation exposures
(Smith et al. 1967; Bakke et al. 1976; Ahdaya and Guthrie 1982; Nolan et
al. 1984), but dermal absorption is low unless skin integrity is compro-
mised (Shah et al. 1987; Aprea et al. 1994). Once absorbed, it is distrib-
uted to all organs and undergoes rapid metabolism. Chlorpyrifos is desul-
fated via cytochrome P450 (CYP450) enzymes to chlorpyrifos-oxon pre-
dominantly in the liver but also in other organs, including the brain
(Chambers and Chambers 1989).
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Chlorpyrifos-oxon binds to and irreversibly inhibits cholinesterases,
such as acetylcholinesterase (AChE), which terminates the action of
acetylcholine at cholinergic synapses in the central and peripheral nerv-
ous system and at neuromuscular junctions (Palmer et al. 1980).
Inhibition of AChE leads to an accumulation of acetylcholine at cholin-
ergic synapses and overstimulation of nicotinic and muscarinic receptors
throughout the body (Richardson 1995; ATSDR 1997; Eaton et al. 2008).
Acute cholinergic toxicity occurs when cholinesterase inhibition exceeds
70% (Clegg and van Gemert 1999), but other adverse effects can occur
with much lower levels of inhibition.
Several cohort studies have examined the association between chlor-
pyrifos exposure and neurodevelopmental outcomes in newborns and
young children (e.g., Perera et al. 2003; Berkowitz et al. 2004; Eskenazi et
al. 2004; Whyatt et al. 2004; Young et al. 2005; Rauh et al. 2006; Engel et al.
2007; Eskenazi et al. 2007; Wolff et al. 2007; Barr et al. 2010). These
cohorts include the Mothers and Newborns Study of North Manhattan
and South Bronx (Columbia University); the Inner-City Toxicants, Child
Growth and Development Study (Mt. Sinai Hospital); the Center for
Health Assessment of Mothers and Children of Salinas Valley (CHAMA-
COS) (University of California/Berkeley); and the University of Medicine
and Dentistry of New Jersey (UMDNJ) cohort. Exposures in these studies
are at least 1,000-fold less than those that inhibit AChE in animals (Eaton
et al. 2008; Prueitt et al. 2011). Multiple studies have been published for
each cohort that evaluate several endpoints, including head circumfer-
ence, infant neurobehavioral capacity, cognitive and motor development,
and behavioral outcomes. Some statistically significant associations were
reported in these studies, so it has been hypothesized that chlorpyrifos
exposure may be associated with neurodevelopmental effects at doses
below the threshold for AChE inhibition via a non-enzymatic role of
AChE in brain development or by other non-cholinergic mechanisms in
the developing nervous system.
In 2011, the United States Environmental Protection Agency
(USEPA) conducted a risk assessment of chlorpyrifos using laboratory
animal brain AChE inhibition data to derive a point of departure (POD)
and for dose-response analysis (USEPA 2011). In a draft issue paper
released this year, USEPA (2012) assessed whether the observational epi-
demiology data suggest that fetal or early-life chlorpyrifos exposure caus-
es neurodevelopmental effects and, if so, whether these effects occur at
exposures below those that inhibit AChE by 10%. If this were the case,
then it might be more appropriate to use neurodevelopmental effects to
determine the POD and dose-response.
To determine how to incorporate the epidemiology data in the chlor-
pyrifos risk assessment, it is critical that the data are first reviewed in a
comprehensive, critical, and transparent manner. We recently conducted
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a hypothesis-based weight-of-evidence (HBWoE) analysis of chlorpyrifos
and neurodevelopmental effects to analyze the evidence regarding the
hypothesis that chlorpyrifos can cause these effects below the threshold
for inhibition of AChE activity in the nervous system (Prueitt et al. 2011).
In this analysis, we systematically reviewed individual studies in tables and
the text, and then integrated all of the relevant data and considered each
line of evidence (e.g., epidemiology, toxicology, and mechanistic) to
inform the integration of other kinds of data and compare alternative
hypotheses. Based on this, we concluded that a causal association
between chlorpyrifos exposure and neurodevelopmental effects in the
absence of AChE inhibition in the brain is not plausible in humans, and
the few positive associations observed in epidemiology studies are most
likely attributable to alternative explanations. We briefly discuss this
analysis and our conclusions here, but the full evaluation can be found in
the Prueitt et al. (2011) paper. Here, we use the results of that analysis to
address the specific question of how the chlorpyrifos toxicology and
mechanistic data can influence the interpretation of epidemiology data,
and how this in turn can be used in a risk assessment.
HYPOTHESIS-BASED WEIGHT-OF-EVIDENCE EVALUATION
Approaches for incorporating epidemiology data in a risk assessment
are no different than those for incorporating other kinds of data. Because
a risk assessment is quantitative, only one study generally can be used to
calculate the POD. To determine which study is most appropriate and
most consistent with the weight of evidence (WoE), a WoE analysis should
be conducted. There are many WoE frameworks available (e.g., Krimsky
2005; ECETOC 2009; Linkov et al. 2009; Rhomberg et al. 2010; USEPA
2010; Rhomberg et al. 2011). The HBWoE framework we used in the
Prueitt et al. (2011) analysis incorporates several aspects of many of the
others and can be summarized in seven steps:
1. Systematically review individual studies relevant to the causal question
at hand, focusing on an evaluation of study quality.
2. Within a given line of evidence [e.g., epidemiology, experimental ani-
mal, or mode of action (MoA) studies], systematically examine the
data for particular endpoints across studies, evaluating the consisten-
cy, specificity, and reproducibility of outcomes.
3. Identify and articulate lines of argument (“hypotheses”) that bear on
the available data and on establishing potential human risk.
4. Evaluate the logic of the proposed hypotheses with respect to each line
of evidence, considering plausibility and consistency across studies.
5. Evaluate the logic of the proposed hypotheses with respect to all lines
of evidence holistically so that all of the data are integrated and
inform the interpretation of one another.
Low-Dose Epidemiology Data in a Chlorpyrifos Risk Assessment
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6. Describe and compare the various alternative accounts of the obser-
vations at hand, with a discussion of how well each hypothesis is sup-
ported by all of the available data, the uncertainties and inconsisten-
cies in the dataset, and any ad hoc assumptions required to support
each hypothesis.
7. Formulate conclusions and any proposed next steps (e.g., sharpening
of proposed hypothesis, additional testing to clarify data gaps).
These steps are described in detail in the Prueitt et al. (2011) publi-
cation. Using this approach, we found that the available epidemiology
studies have imprecise exposure estimates that were measured at only one
time point, sometimes reflected exposures to other pesticides, and often
covered a small range and had many values below the limit of quantifica-
tion. These studies do not report consistent associations, in that statisti-
cally significant associations were not reported for the same or related
endpoints either within or among studies. That is, in cases when chlor-
pyrifos exposure was estimated using different surrogates, even in the
same study, results based on different surrogates were not consistent. For
example, results would be null for some metrics and positive for others,
or sometimes in opposite directions for different metrics. There was also
a lack of clear exposure-response relationships. We concluded that the
reported associations in these studies are less likely to be indicative of cau-
sation and more likely to be a result of alternative explanations, such as
exposure measurement error, bias, or confounding (Prueitt et al. 2011).
We also found that the animal toxicity data are themselves inconsis-
tent in demonstrating neurodevelopmental impacts, and doses suggest-
ing such effects are either associated with AChE inhibition or are at lev-
els expected to cause such inhibition based on other experiments
(Prueitt et al. 2011). This is also true for the majority of in vitro studies.
Consequently, there is no positive evidence that chlorpyrifos is associated
with neurodevelopmental effects at doses below the threshold for inhibi-
tion of AChE in the brain. Measurements and pharmacokinetic modeling
show that human exposures, including those in the existing epidemiolo-
gy studies, are far below those capable of causing meaningful AChE inhi-
bition, which supports the interpretation that any associations reported
in epidemiology studies are not causally related to chlorpyrifos exposure.
Overall, the weight of available evidence more strongly indicates that a
causal association between chlorpyrifos exposure and neurodevelopmen-
tal effects in the absence of AChE inhibition in the brain is not plausible
for humans, and the few positive associations observed in epidemiology
studies are attributable to alternative explanations (Prueitt et al. 2011).
J. E. Goodman and others
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HAZARD CHARACTERIZATION
The mechanistic experimental toxicity data do not yet support a
coherent set of key events in a MoA/adverse outcome pathway for neu-
rodevelopmental effects of chlorpyrifos. As discussed in detail in the
Prueitt et al. (2011) evaluation, the specific mechanisms proposed to sup-
port the hypothesis that chlorpyrifos induces adverse neurodevelopmen-
tal effects at doses below those that inhibit the activity of AChE in the
brain involve the action of chlorpyrifos itself, rather than chlorpyrifos-
oxon, and have been suggested to be involved in a large spectrum of
effects. These include neuronal cell damage, disruption of systems con-
trolling neuronal differentiation and synaptic function, and serotonergic
dysfunction.
Evidence for the action of the proposed mechanisms at doses not
affecting AChE activity comes mainly from in vitro studies, so relevance to
potential outcomes in children with very low exposures to chlorpyrifos
depends on tying levels in these in vitro experiments to the levels that
would occur in children. Several physiologically based pharmacokinet-
ic/pharmacodynamic (PBPK/PD) models are available for correlation of
in vitro chlorpyrifos concentrations to systemic levels in vivo (e.g.,
Timchalk et al. 2002, 2007). Recently, estimates of in vivo exposure equiv-
alents determined with a LifeStage PBPK/PD model indicate that most
doses in the in vitro chlorpyrifos studies were at or above levels that would
inhibit AChE (Bartels et al. 2012). Of those in vitro studies with doses
below those that cause AChE inhibition, it must be considered that con-
founding experimental factors (such as the use of DMSO as a vehicle or
non-specificity of the assay) could be causing the biological effects rather
than chlorpyrifos.
In addition, there is very little in vivo evidence for the proposed
mechanisms acting through chlorpyrifos at doses below those that inhib-
it AChE activity (as reviewed by Prueitt et al. 2011). Only one study report-
ed effects on synaptic proliferation and activity observed in rats exposed
to 1 mg/kg-day chlorpyrifos during gestational day (GD) 17-20 (Qiao et
al. 2003), a treatment that was not associated with AChE inhibition in the
brain in another study when assessed 24 hours after exposure cessation
(Qiao et al. 2002). In all but this in vivo study, there is no evidence for an
absence of AChE inhibition. Because the metabolite chlorpyrifos-oxon is
markedly more potent than the parent chlorpyrifos in inhibiting AChE
(Huff et al. 1994; Das and Barone 1999), it is presumed to be present in
the nervous system during any exposures sufficient to inhibit AChE.
Thus, chlorpyrifos-oxon could be driving the specific mechanisms
through its propensity to bind to proteins, an effect that would be absent
at doses below those causing AChE inhibition.
The large body of neurodevelopmental data in experimental animals
is limited by the small numbers of doses used in each study. Other issues
Low-Dose Epidemiology Data in a Chlorpyrifos Risk Assessment
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with study quality are discussed in our recent evaluation of these data
(Prueitt et al. 2011). For example, the majority of studies used subcuta-
neous injection as the exposure route, which, by avoiding the extensive
first-pass metabolism of ingested chlorpyrifos, is not as relevant to
humans (e.g., see Smith et al. 2009). Studies using the more relevant oral
exposure route do not appear to be more likely to report associations
with neurodevelopmental effects. In fact, when we examined the studies
with the most weight separately (e.g., those that used dose groups with a
relatively high number of animals of each sex), considering both oral and
subcutaneous exposures and including the one study that complied with
USEPA Pesticide Assessment Guidelines and Good Laboratory Practice
(GLP) regulations, we found largely null effects were reported across var-
ious neurodevelopmental tests. Those that did report treatment-related
effects often reported inhibition of AChE activity in the brain at the same
doses, suggesting that effects occur via this pathway or at least at doses
that can cause AChE inhibition. Overall, we found that the animal data
available to date do not indicate that chlorpyrifos causes neurodevelop-
mental effects at exposure levels below those associated with AChE inhi-
bition (Prueitt et al. 2011).
Chlorpyrifos exposures in epidemiology studies are much lower than
those used in the animal and in vitro studies discussed above. For exam-
ple, five-day-old rat pups exposed to 1 mg/kg chlorpyrifos had maximum
blood concentrations at two hours post-dosing between 16 and 140 nM,
resulting in estimated brain concentrations of 0.5-4.6 μM (Marty et al.
2007). AChE inhibition and mechanistic effects were also reported at
micromolar concentrations in the in vitro studies, with three exceptions
(Das and Barone 1999; Schuh et al. 2002; Howard et al. 2005). In contrast,
chlorpyrifos concentrations in the brain of subjects in the Columbia
cohort were estimated to be from 0.33-3.3 nM (Eaton et al. 2008). These
data indicate that estimated exposures to chlorpyrifos in the cohort stud-
ies are at least 1,000-fold lower than those used in the animal studies or
those at which effects, including AChE inhibition, were observed in most
of the in vitro mechanistic studies.
Regarding the epidemiology literature, we found that it is just as like-
ly that reported positive associations are a result of alternative factors
(e.g., bias, confounding, exposure misclassification, statistical artifact) as
opposed to indicative of a causal relationship (Prueitt et al. 2011). The
results are not consistent or coherent across studies, and no clear expo-
sure-response association has been demonstrated. Issues with exposure
estimates also likely biased results. The animal and mechanistic data
described above also cast doubt on the plausibility of a causal association
in humans at exposures below those that inhibit AChE. This informs the
hazard characterization in that the lack of consistent effects supports
AChE inhibition as the relevant MoA for risk assessment.
J. E. Goodman and others
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DOSE-RESPONSE ANALYSIS
Although the conclusions of the hazard assessment above, which is
based on our WoE evaluation (Prueitt et al. 2011), indicate that the epi-
demiology data are not sufficient to conclude effects at exposures below
those that cause AChE inhibition, epidemiology data has been used in
the past for deriving a POD and in dose-response analyses. In 2008,
USEPA’s Science Advisory Panel (SAP) specifically cautioned against
using Columbia cohort data for deriving a POD for chlorpyrifos because
biomarkers were only measured at one point in time and effects may have
been due to chlorpyrifos in combination with other pesticides (USEPA
2008). The 2008 SAP also advised against using any of the chlorpyrifos
cohort studies because of limitations of the exposure assessment, “e.g.,
lack of repeated exposure estimates to ascertain more specifically the vari-
ability and periodicity of exposure over time.” Other issues with exposure
estimates, described below, affect the reliability of these measurements
and confirm that they should not be used in a dose-response assessment.
AChE inhibition data are the most robust source of dose-response
data for deriving PODs for the chlorpyrifos risk assessment. These data
take into account the most sensitive lifestages for exposure to chlorpyri-
fos (i.e., pregnant women and their fetuses, newborns, and young chil-
dren), and the use of AChE inhibition as a regulatory endpoint is pro-
tective of downstream cholinergic effects. Although some of the neu-
rodevelopmental and mechanistic studies suggest there are non-cholin-
ergic effects of chlorpyrifos on the developing brain, a quantitative
method to relate the effect levels for AChE inhibition and potential non-
cholinergic effects can help determine whether AChE inhibition contin-
ues to be the most sensitive endpoint – and therefore protective against
other effects. To date, such analyses suggest that the levels would be sim-
ilar (Bartels et al. 2012), which is consistent with the lack of evidence for
non-cholinergic effects at doses that do not also inhibit AChE activity.
That is, the models serve to help tie MoA data from different kinds of
experiments into a coordinated set of bases for inferring possible human
impacts and the exposures necessary to cause them. The dose-response
for pharmacokinetic effects inform the plausible dose-response for mech-
anistic effects that have not been investigated directly at low doses.
EXPOSURE CHARACTERIZATION
Chlorpyrifos exposures have been estimated using several different
metrics across epidemiology studies. The best estimate, which was used in
the Columbia cohort, is based on a chlorpyrifos measurement directly in
blood. Plasma and cord blood were taken at delivery, however, so expo-
sures during early central nervous system development are unknown.
Low-Dose Epidemiology Data in a Chlorpyrifos Risk Assessment
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The majority of samples were below the limit of detection and it is unclear
how precise the measurements near the limit of detection were.
The chlorpyrifos metabolites 3,5,6-trichloro-2-pyridinol (TCPy),
diethylphosphate (DEP), and diethylthiophosphate (DETP) have also
been measured in urine (e.g., Barr et al. 2005). Urinary TCPy originates
not only from exposure to chlorpyrifos, but also TCPy itself (in the form
of residues on foodstuffs from environmental degradation of chlorpyri-
fos) and other pesticides such as chlorpyrifos-methyl and triclopyr
(MacIntosh et al. 1999; Morgan et al. 2005; Needham 2005). Urinary DEP
and DETP can also originate from exposure to other pesticides, such as
diazinon and disulfoton, and to pre-formed, environmental DEP and
DETP (Needham 2005; Wessels et al. 2003). Activities of erythrocyte
AChE or plasma butyrylcholinesterase (BuChE) also have been used as
biomarkers of chlorpyrifos exposure, but these activities are not specific
to chlorpyrifos; other chemicals, including other OP and N-methyl car-
bamate pesticides, can inhibit cholinesterases (ATSDR 1997; Barr and
Angerer 2006).
The limitations in exposure estimates preclude one from determin-
ing precise exposures. When considered with pharmacokinetic data, how-
ever, they can provide information on exposure levels relative to those
used in experimental studies. It appears that maternal exposures to chlor-
pyrifos are about three orders of magnitude lower than those that cause
AChE inhibition and other effects.
ESTIMATING THE RANGE OF POSSIBLE RESPONSES AT TYPICAL HUMAN
EXPOSURE LEVELS
A WoE evaluation regarding the presence of risks at typical human
exposure levels is an exercise in evaluating the uncertainty in the infer-
ences about whether such risks exist from different available sources of
data. Even when definitive quantitative modeling is difficult, using PBPK
and dose-response models while varying assumptions in scientifically
plausible ways can be an important tool in assessing whether proposed
mechanisms are plausible causes at the low levels of human exposure.
In particular, the chlorpyrifos animal and in vitro data that suggest
non-cholinergic mechanisms of impact on the development of the nerv-
ous system are largely seen at rather high doses, and the extrapolation of
the magnitude of these effects to humans at lower doses is hampered by
lack of multiple-dose studies or because the relation of in vitro exposures
to tissue levels in humans at sensitive stages is in question. Even if dose-
response evaluation of such factors cannot be done definitively, it is pos-
sible to use PBPK and hypothetical dose-response patterns to identify the
range of plausible measures of these factors that might appear in the
human tissues at risk. For instance, as we argued in our HBWoE analysis
on chlorpyrifos (Prueitt et al. 2011), the MoA of most proposed non-
J. E. Goodman and others
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cholinergic effects seems to involve the production and binding of chlor-
pyrifos or its metabolites, notably chlorpyrifos-oxon, to key proteins.
Pharmacokinetic models and plausible dose-response patterns for such
models, and for the relative degrees of protein binding implied, inform
the evaluation of whether such processes would be likely to act with suffi-
cient magnitude to result in adverse outcomes at expected human doses
and at doses well below those that cause AChE inhibition. That is, even if
these projections are in some degree hypothetical, it is possible to con-
clude that they would not plausibly operate with sufficient magnitude to
cause dysfunction at human exposures – if even a wide range of projec-
tions does not include the values that would be of concern. Even such
uncertain projections can be useful in ruling out the role of the factors
discussed above in producing low-dose human hazard.
There is little evidence that proposed non-cholinergic mechanisms
occur at doses lower than those that cause cholinesterase inhibition. The
effects depend to a large degree on a common set of chlorpyrifos metabo-
lites as the primary active agents. The diminution of the production of
these metabolites and the consequent amount of protein binding with
lower doses makes it implausible to consider that the effects are sufficient
to cause dysfunction at human dose levels.
The evaluation of animal and mechanistic data provide evidence that
calls into question the plausibility of chlorpyrifos to be able to affect neu-
rodevelopment at low human doses. If there were any ability of chlor-
pyrifos to act at low doses, it would have to be by some novel hypothetical
mechanism for which there is currently no strong evidence. The epi-
demiology data alone do not make a compelling case for the existence of
a chlorpyrifos effect – a causative interpretation based solely on the
observed patterns of association is not markedly different in plausibility
from explanations that attribute these outcomes to chance or confound-
ing. It is not merely that the animal data do not support a causal associa-
tion in epidemiology studies, they actually cast doubt on the biological
plausibility of such a conclusion, in that they provide evidence against a
causal association at human-relevant exposures of chlorpyrifos.
Even though AChE inhibition is an acute endpoint from which one
can recover, maintaining exposures low enough to avoid inhibition also
protects against any chronic effect that requires ongoing exposures at lev-
els above those limits. The issue arises when one exceeds the acute-effect
dose restriction for a short time – one risks the acute effect but not the
chronic one unless the exceedance goes on long enough. In other words,
if an acute and a chronic effect had the same threshold, the issue would
be whether protecting against the chronic effect (which needs super-
threshold doses for some run of time) would protect against the acute
effect (which needs only a single exceedance), not the other way around.
If AChE inhibition is mechanistically required to bring about the high-
Low-Dose Epidemiology Data in a Chlorpyrifos Risk Assessment
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dose neurodevelopmental effects seen in animals, then exposures that
avoid such inhibition clearly avoid the developmental consequences as
well. But even if the neurodevelopmental impacts have a non-cholinergic
MoA, the preponderance of evidence (as discussed by Prueitt et al. 2011)
suggests that such mechanisms would require doses at or near those also
causing AChE inhibition. Thus, the current approach of using AChE
inhibition as a sensitive endpoint and the basis for limiting exposures
should protect against any neurodevelopmental risk as well.
In conclusion, an HBWoE evaluation of the relevant epidemiology,
toxicology, and mechanistic data indicates that statistically significant
associations in epidemiology studies are not likely indicative of causation
(Prueitt et al. 2011). There appears no substantial basis to abandon
USEPA’s stance that exposure restrictions that protect against AChE inhi-
bition will be protective not only of the general population, but also those
at the most sensitive lifestages for exposure to chlorpyrifos (i.e., pregnant
women and their fetuses, newborns, and young children). Since that basis
is well established and well documented, it should be retained. No addi-
tional uncertainty factors need be applied to allow for the possibility of
effects in sensitive populations at exposures already limited to avoid
AChE inhibition because the MoA information indicates the implausibil-
ity of such effects, and the epidemiology data alone provide no com-
pelling basis to conclude otherwise.
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